hsa-mir-579: Hsa-mir-579 is an intronic miRNA that is associated with the TP53 gene and has been found to alter the binding sites of various miRNAs, including hsa-miR-1224-5p and hsa-miR-1265 [PMC8956157]. It has been suggested that differential intronic miRNA processing may be one mechanism of regulation [PMC4370670]. The binding site for hsa-mir-579 is located in the longest UTR isoform of its host gene, ZFR, at nucleotide position 1301 after the CDS [PMC4370670]. Experimental validation of the direct binding and targeting of hsa-mir-579 to ZFR has been performed using a subcloned 32UTR in a vector [PMC4370670]. Hsa-mir-579 does not have an individual promoter region and appears to be co-expressed with its host gene [PMC4370670]. It has been found to be related to bevacizumab-induced cardiotoxicity, but its expression in the human brain and neuronal function have not yet been described [PMC6195525]. Hsa-mir-579 has also been identified as one of the top altered miRNAs after IL-1β exposure in A549 cells [PMC5349881]. It has shown a modest relative increase in expression in AD PBMCs, along with other miRNAs such as hsa-miR-34a and hsa-miR-155 [PMC4053778]. Additionally, it has been identified as one of several differential miRNAs associated with low and high TMB in LIHC patients [PMC7355149]. Hsa-mir-579 has also been reported to inhibit the transcription of its host gene ZRF by binding to its 3'-UTR [PMC8408170], and it has been predicted to bind with circ_0088300 [PMC8188357]. Furthermore, it has been identified as one of the miRNAs predicted to interact with ANXA2 mRNA [PMC5950137]. Finally, hsa-mir-579 has been found to target multiple genes, including SPRY2, YBX2, and GNAS family proteins [PMC5776763][PMC4786758].